Neither GLP-1 receptors nor GFRAL neurons are required for aversive or anorectic response to DON (vomitoxin). 2023

Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
Neuroscience Graduate Program, University of Michigan-Ann Arbor, Ann Arbor, MI, United States.

Deoxynivalenol (DON), a type B trichothecene mycotoxin contaminating grains, promotes nausea, emesis and anorexia. With DON exposure, circulating levels of intestinally derived satiation hormones, including glucagon-like peptide 1 (GLP-1) are elevated. To directly test whether GLP-1 signaling mediates the effects of DON, we examined the response of GLP-1 or GLP-1R-deficient mice to DON injection. We found comparable anorectic and conditioned taste avoidance learning responses in GLP-1/GLP-1R deficient mice compared to control littermates, suggesting that GLP-1 is not necessary for the effects of DON on food intake and visceral illness. We then used our previously published data from translating ribosome affinity purification with RNA sequencing (TRAP-seq) analysis of area postrema neurons that express the receptor for the circulating cytokine growth differentiation factor (GDF15), growth differentiation factor a-like (GFRAL). Interestingly, this analysis showed that a cell surface receptor for DON, calcium sensing receptor (CaSR), is heavily enriched in GFRAL neurons. Given that GDF15 potently reduces food intake and can cause visceral illness by signaling through GFRAL neurons, we hypothesized that DON may also signal by activating CaSR on GFRAL neurons. Indeed, circulating GDF15 levels are elevated after DON administration but both GFRAL knockout and GFRAL neuron-ablated mice exhibited similar anorectic and conditioned taste avoidance responses compared to WT littermates. Thus, GLP-1 signaling and GFRAL signaling and neurons are not required for DON-induced visceral illness or anorexia.

UI MeSH Term Description Entries

Related Publications

Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
September 1985, Cell,
Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
January 2022, Molecular metabolism,
Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
July 2015, Toxins,
Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
January 2011, The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha,
Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
January 1984, The Journal of molecular and cellular immunology : JMCI,
Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
April 1999, Endocrinology,
Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
November 2014, Chronobiology international,
Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
March 2020, Science translational medicine,
Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
August 2002, BMJ (Clinical research ed.),
Anita R Patel, and Henriette Frikke-Schmidt, and Paul V Sabatini, and Alan C Rupp, and Darleen A Sandoval, and Martin G Myers, and Randy J Seeley
August 1998, Cancer research,
Copied contents to your clipboard!